other material
confidence high
sentiment positive
materiality 0.30
Chromocell authorizes $250K stock repurchase plan; up to ~23% of non-affiliate float
Pelthos Therapeutics Inc.
- Authorized repurchase of up to $250,000 of common stock, representing ~23% of non-affiliate float.
- Repurchases may occur via open market or private transactions through Dec 31, 2024.
- CEO states stock price does not reflect progress in developing non-opioid pain treatments.
- Plan does not obligate company to repurchase any shares; may be modified or terminated.